Research Divisions

Movement Disorders


Our Parkinson's Disease and Movement Disorder Center at Pennsylvania Hospital, with its comprehensive medical and surgical therapies and experimental therapeutics arsenal, is unrivaled in the region and is internationally recognized for both its clinical and diverse research programs. With the National Parkinson Foundation Center of Excellence at Pennsylvania Hospital and one of only six national Centers of Excellence at the Philadelphia Veterans Administration Hospital, The Penn program continues to lead the way in reducing the impact of these disorders. In addition, we have recently re-established a Huntington’s Disease Program at PAH, with cutting edge therapeutic trials and genetic counseling.

Centers and Programs

Labs

Clinical Trials

Huntington’s Disease

Open label extension study of pridopidine (ACR16) in the symptomatic treatment of Huntington’s disease (Open Hart)
PI: Pedro Gonzalez-Alegre
Coordinator: Devin Keating
devin.keating@uphs.upenn.edu
http://clinicaltrials.gov/ct2/show/NCT01306929

A prospective registry study in a global Huntington’s disease cohort (Enroll HD)
PI: Pedro Gonzalez-Alegre
Coordinator: Devin Keating
devin.keating@uphs.upenn.edu
http://clinicaltrials.gov/ct2/show/NCT01574053


Parkinson’s Disease

Disease modifying potential of transdermal NICotine in Early PD (NIC-PD)
PI: Andres Deik
Coordinator: Reema Patel
reema.patel@uphs.upenn.edu
http://clinicaltrials.gov/ct2/show/NCT01560754

Efficacy of isradipine in early Parkinson’s disease (Steady PD)
PI: Andres Deik
Coordinator: Reema Patel
reema.patel@uphs.upenn.edu
http://clinicaltrials.gov/ct2/show/NCT02168842

Study of Urate elevation in Parkinson’s disease, Phase 3 (SURE-PD3)
PI: Andres Deik
Coordinator: Reema Patel
reema.patel@uphs.upenn.edu
http://clinicaltrials.gov/ct2/show/NCT02642393

Safety and efficacy study of tozadenant to treat end of dose wearing off in Parkinson’s disease patients using Levodopa (Toz-PD)
PI: Spindler
Coordinator: Devin Keating
devin.keating@uphs.upenn.edu
http://clinicaltrials.gov/ct2/show/NCT02453386

SYN120 a dual 5-HT6/5-HT2A Antagonist proof of concept study to evaluate its safety, tolerability and efficacy in Parkinson’s disease dementia (SYNAPSE),
PI: Dahodwala
Coordinator: Gina
eugenia.mamikonyan@uphs.upenn.edu
http://clinicaltrials.gov/ct2/show/NCT02258152

Study to identify clinical, imaging and biologic markers of Parkinson’s disease progression (PPMI)
PI: Chahine
Coordinator: Carly
carly.linder@uphs.upenn.edu
http://clinicaltrials.gov/ct2/show/NCT01141023

Systemic synuclein sampling (S4)
PI: Chahine
Coordinator: Carly
carly.linder@uphs.upenn.edu
http://clinicaltrials.gov/ct2/show/NCT02572713

Udall (NIH)
PI: Weintraub
Coordinator: Ben

© The Trustees of the University of Pennsylvania | Site best viewed in a supported browser. | Site Design: PMACS Web Team.